Given the limited data on the real‐life therapeutic use of feline McDonough sarcoma (FMS)‐like tyrosine kinase 3 (FLT3) inhibitors in Italy, we surveyed investigators at 59 Italian hematology centers to gain insight into the proportion of acute myeloid leukemia (AML) patients receiving FLT3 inhibitors and we collected data on the efficacy and safety of these agents. Here, FLT3 is linked to acute myeloid leukemia.